摘要
目的探讨阿立哌唑治疗抗精神病药物(APS)所致高催乳素血症的疗效及安全性。方法60例APS所致高催乳索血症患者,维持原APS治疗方案。随机分组后,分别加用阿立哌唑5mg(30例)及安慰剂(30例)进行对照治疗,疗程6周。于治疗前、治疗后6周检测催乳素(PRL)；观察高催乳素血症临床症状变化情况；以简明精神病量表(BPRS)及副反应量表(TESS)评定对原APS治疗疗效的影响及其他不良反应。结果阿立哌唑组研究结束时PRL[(27．5±8．2)μg·L^(-1)]较基线[(148．7±45．5)μg·L^(-1)]下降,差异具有显著性(P＜0．001)；安慰剂组研究结束时PRL[(122．4±72．2)μg·L^(-1)]与基线[(134．4±58．8)μg·L^(-1)]比较,差异无显著性(P＞0．05)；阿立哌唑组月经恢复(27/28)、自发泌乳消失(16/16),安慰剂组则均无改善。2组不良反应均轻,总体发生率相当,对原APS治疗的疗效均无不良影响。结论阿立哌唑治疗抗精神药物所致高泌乳血症有效、安全。
Objective To explore the efficacy and tolerability of aripiprazole in the treatment of hyperpro-lactinemia by antipsychotics origin. Methods 60 schizophrenic patients with hyperprolactinemia by antipsychotics origin were randomly assigned to aripiprazole group （ n = 30） and placebo group （ n = 30） for 6 weeks , while receiving original antipsychotics treatment. The prolactin （PRL） was measured at the baseline and end of study, same as the clinical symptoms of hyperprolactinemia were evaluated. The adverse effects on original antipsychotics treatment and other side effects were assessed with the Brief Psychiatric Rating Scale （BPRS） and the Treatment E- mergent Symptom Scale （TESS） before and after the study. Results The concentration of PRL was lower after the study [ （27.5 ± 8.2） μg·L^-1] than before the study [ （ 148.7 ± 45.5 ）μg·L^-1 ] in aripiprazole group, and the difference was statistically significant（ P〈 0. 001 ）, however this difference in placebo group was not statistically significant before and after the study （ P 〉 0.05 ）. Disappearment of amenia （27/28） and spontaneous lactation （16/16） were observed in aripiprazole group, while not any change occurred in placebo group. No adverse effects on original antipsychotics treatment were recorded in any group. Other side effects were mild and the total prevalence of side effects was similar in both groups. Conclusions Aripiprazole is effective and safe in the treatment of hyperprolactinemia by antipsychotics origin.
出处
《中国行为医学科学》
CSCD
2006年第8期718-720,共3页
Chinese Journal of Behavioral Medical Science
